NCT04809467 2026-02-04
topMIND
Incyte Corporation
Phase 1/2 Terminated
Clinical Trials
4 trialsNCT04661007 2025-12-18
J-MIND
Incyte Corporation
Phase 1/2 Active not recruiting
NCT02018861 2023-09-28
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Incyte Corporation
Phase 1/2 Completed
NCT02265510 2020-04-17
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated